Nasus Pharma Ltd. (NSRX) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Nasus Pharma Ltd. (NSRX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $26.0M, listed on AMEX, employing roughly 2 people, carrying a beta of 3.89 to the broader market. Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Led by Dan Teleman, public since 2025-08-13.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for NSRX as of 2026-06-01; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →